Location
United Kingdom, Europe
Cheque size
$200K - $3M
Investment Stage
Focus Areas
About Investor
Cornel Chiriac is an Investment Director at M&G Investments' Crossover Fund and Founding Partner of 2050 Capital, based in London, United Kingdom, specializing in venture capital and growth-stage investments in deep technology, scientific innovation, and enterprise technology. At M&G Investments, he focuses on growth and late-stage technology companies, with institutional investment tickets ranging from £25 million to £50 million. Alongside this role, he remains associated with 2050 Capital, a London-based early-stage investment firm focused on science-driven businesses and technically differentiated innovations. His investment interests span Artificial Intelligence (AI), DeepTech, BioTech, Computational Biology, Enterprise Software, SaaS, Cloud Infrastructure, Cybersecurity, Advanced Materials, ClimateTech/CleanTech, ConstructionTech, and Industrial Technology, with particular expertise in scientific computing, engineering software, and biotechnology. His investment experience covers Pre-seed, Seed, Series A, and later-stage growth financing, although his early-stage investment strategy at 2050 Capital primarily emphasizes Seed investments. According to his Signal investor profile, his estimated early-stage investment range is $200,000 to $3 million, with a preferred ticket of approximately $250,000. His published investment criteria indicate that 2050 Capital typically invests $200,000–$500,000 in initial Seed rounds, with follow-on investments of up to $3 million, generally completing two to six new investments annually. His documented investment portfolio includes Hadean, AMFG, TypeDB (formerly Vaticle/Grakn), Origin Sciences, KETS Quantum Security, and One Silicon Chip Photonics (OSCP), demonstrating exposure to high-performance computing, advanced manufacturing, knowledge graphs, biotechnology, quantum security, and photonic sensing. Through M&G Investments, he has also been involved with bit.bio and 4basebio, two biotechnology companies developing technologies for advanced medical research and genetic medicines. Cornel has confirmed lead investor experience, having led Seed investment rounds in Hadean, AMFG, TypeDB, and Origin Sciences through 2050 Capital. He also participates in institutional growth financing, including M&G's investment activities involving bit.bio and 4basebio. Before establishing 2050 Capital, Cornel worked as a strategy and transaction consultant at L.E.K. Consulting, participated in corporate venture capital activities at the World Gold Council, and held operational and executive positions in technology and industrial businesses. Earlier in his career, he built and scaled two ventures in the United States that achieved multimillion-dollar exits. He is also an Investment Director and Management Committee Member of the Chicago Booth Angels Network, supporting angel investment activities and entrepreneurial development. Cornel holds an MBA from the University of Chicago Booth School of Business, with concentrations in finance, accounting, entrepreneurship, and strategic management. In July 2026, he was appointed a Non-Executive Director of 4basebio, further strengthening his involvement in biotechnology commercialization and corporate governance. Through his extensive experience in venture capital, growth equity, entrepreneurship, and corporate strategy, Cornel supports founders with fundraising, technical due diligence, scientific commercialization, investment structuring, strategic partnerships, corporate governance, international expansion, and scaling research-intensive technology businesses.
Previous investments
Similar Investors
Joaquin Gomez
Pre Seed
,Seed
,William Tunstall-Pedoe
Pre Seed
,Seed
,Christoph Janz
Pre Seed
,Seed
,Igor Tikhturov
Pre Seed
,Seed
,Eze Vidra
Pre Seed
,Seed
,Pierre-Eric Leibovici
Seed
,Series A
,Is this Your Profile?
If you have any updates, please fill out our form.
